Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06468826 · ClinicalTrials.gov registry record · Phase 1
A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT06468826 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 13 participants.
The verdict
NCT06468826, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of avacopan and metabolite (M1) after a single dose of avacopan in participants with normal renal function and participants with ESRD requiring hemodialysis (HD).
Interventions
- DRUG Avacopan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2024-06-18 |
| Est. Completion | 2024-10-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06468826
The ClinicalTrials.gov registry entry for NCT06468826 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avacopan is the first listed.
NCT06468826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06468826 about?
NCT06468826 is a clinical study titled "A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)". The primary objective of the study is to evaluate the pharmacokinetics (PK) of avacopan and metabolite (M1) after a single dose of avacopan in participants with normal renal function and participants with ESRD requiring hemodialysis (HD).
What is the current status of trial NCT06468826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2024-06-18. Estimated completion is 2024-10-05.
What interventions are being tested in trial NCT06468826?
The interventions under investigation include: Avacopan (DRUG).
Who is sponsoring clinical trial NCT06468826?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.